Sudeep Pharma Limited (BOM:544619)

Market Cap	131.83B
Revenue (ttm)	6.76B +31.8%
Net Income	1.83B +33.7%
EPS	16.21 +29.2%
Shares Out	n/a
PE Ratio	71.64
Forward PE	65.03
Dividend	1.50 (0.13%)
Ex-Dividend Date	Jul 23, 2026

Volume	16,100
Open	1,155.00
Previous Close	1,158.10
Day's Range	1,120.00 - 1,180.75
52-Week Range	524.95 - 1,376.00
Beta	n/a
Analysts	Sell
Price Target	777.50 (-33.37%)
Est. Earnings	Nov 5, 2026

About Sudeep Pharma

Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in India, the United States, and internationally. The company provides mineral salts, such as iron, calcium, sodium, zinc, copper, magnesium, manganese, potassium, picolinates, simethicone, and others;It also offers micronutrient premixes and liposomal, encapsulated ingredients, spray-dried formats, granulated ingredients, and triturated for sports nutrition, medical and clinical nutrition, infant nutrition, b...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1989
• Employees: 525
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544619

Financial Performance

In fiscal year 2026, Sudeep Pharma's revenue was 6.42 billion, an increase of 27.94% compared to the previous year's 5.02 billion. Earnings were 1.73 billion, an increase of 24.63%.

Analyst Summary

According to 2 analysts, the average rating for 544619 stock is "Sell." The 12-month stock price target is ₹777.50, which is a decrease of -33.37% from the latest price.

Price Target

₹777.50

(-33.37% downside)

Analyst Consensus: Sell

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 7, 2026

Data Sources Report a data error